<DOC>
	<DOC>NCT01143090</DOC>
	<brief_summary>Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The purpose of this study is to characterize the long-term safety and tolerability of lurasidone in subjects with schizophrenia or schizoaffective disorder and to allow for continued treatment for subjects completing the core study (D1050289-NCT01143077).</brief_summary>
	<brief_title>A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Subject has completed 6 weeks of treatment and all required assessments on the final study visit (Visit 8) of Study D1050289 (NCT01143077). Subject is considered by the investigator to be at imminent risk of suicide or harm to self, others, or damage to property. Subject has a body mass index (BMI) greater than 40 or less than 18 kg/m2 (see Appendix 3 for BMI determination).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Lurasidone</keyword>
	<keyword>Latuda</keyword>
</DOC>